Internal Medicine Alert - March 30, 2006

Target Audience:

This activity is intended for the internist and family practitioner.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. AAFP accreditation begins 01/01/06. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of this issue.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editors
Stephen A. Brunton, MD
Clinical Professor
University of California
Irvine

Peer Reviewer
Gerald Roberts, MD
Assistant Clinical Professor of Medicine
Albert Einstein College of Medicine
New York, NY

Associate Editors
Joseph E. Scherger, MD, MPH
Clinical Professor
University of California
San Diego

Allan J. Wilke, MD
Residency Program Director
Associate Professor of Family Medicine
University of Alabama at Birmingham School of Medicine?Huntsville Regional
Medical Campus
Huntsville

Mary Elina Ferris, MD
Clinical Associate Professor
University of Southern California

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Manager
Kaiser Permanente
Oakland, CA

William T. Elliott, MD, FACP
Chair
Formulary Committee
Northern California Kaiser Permanente;
Asst. Clinical
Professor of Medicine
University of California
San Francisco

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville

Authors
Michael H. Crawford, MD
Professor of Medicine
Chief of Clinical Cardiology
University of California
San Francisco

Stan Deresinski, MD, FACP
Clinical Professor of Medicine
Stanford
Associate Chief of Infectious Diseases
Santa Clara Valley Medical Center

Subjects:

  • In Search of the Healthy Diet
  • PDE5 Inhibition: New Drug for Raynaud Disease?
  • Troponin vs CKMB in ACS
  • A Normal Temperature May Not Be What We Were Taught
  • An Upgraded Blood Test That Identifies Tuberculous Infection
  • Insulin Human Inhalation Powder (Exubera®)
  • Clinical Briefs

Objectives:

  • Describe new findings in differential diagnosis and treatment of various diseases
  • Describe controversies, advantages, and disadvantages of those advances
  • Describe cost-effective treatment regimens

Financial Disclosure:

Editor, Stephen Brunton, MD, is a consultant for Sanofi-Aventis, Ortho-McNeil, McNeil, Abbott, Novo Nordisk, Eli Lilly, Endo, EXACT Sciences, and Astra-Zeneca, and serves on the speaker’s bureau of McNeil, Sanofi-Aventis, and Ortho-McNeil. Peer reviewer Gerald Roberts, MD, and Associate Editors Joseph E. Scherger, MD, MPH, Allan J. Wilke, MD, Mary Elina Ferris, MD , James Chan, PharmD, PhD , and William T. Elliott, MD, FACP all report no financial relationship to this field of study. Michael H. Crawford, MD is on the speaker's bureau for Pfizer. Louis Kuritzsky, MD is a consultant for GlaxoSmithKline and is on the speaker’s bureau of GlaxoSmithKline, 3M, Wyeth-Ayerst, Pfizer, Novartis, Bristol-Myers Squibb, AstraZeneca, Jones Pharma, and Boehringer Ingelheim. Stan Deresinski, MD, FACP, serves on the speaker’s bureau of Merck, Pharmacia, GlaxoSmithKline, Pfizer, Bayer, and Wyeth, and does research for Merck.

Copyright 2006 AHC Media. All rights reserved.